Hancock Whitney Corp Blueprint Medicines Corp Transaction History

Hancock Whitney Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 26, 2022	BUY	$49.93 - $77.7 $288,445 - $448,872	5,777 New	5,777 $381,000
Q2 2022 Aug 08, 2022	SELL	$45.23 - $70.15 $185,895 - $288,316	-4,110 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$54.1 - $110.08 $22,505 - $45,793	-416 Reduced 9.19%	4,110 $263,000
Q4 2021 Jan 25, 2022	SELL	$94.25 - $115.99 $49,575 - $61,010	-526 Reduced 10.41%	4,526 $485,000
Q3 2021 Nov 04, 2021	SELL	$80.98 - $109.47 $2,105 - $2,846	-26 Reduced 0.51%	5,052 $519,000
Q2 2021 Aug 09, 2021	BUY	$82.78 - $101.0 $8,774 - $10,706	106 Added 2.13%	5,078 $447,000
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $7,619 - $9,095	-84 Reduced 1.66%	4,972 $483,000
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $465,556 - $629,370	5,056 New	5,056 $567,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

Stay updated on Hancock Whitney Corp with notifications on news.